ABIVAX's ABVX stock exploded 39% on June 30, its biggest single-session move in months, yet the lending market tells a story of shorts who aren't backing down.
The catalyst appears to be continued momentum around the phase 2b trial for ABV-1454, ABIVAX's lead program targeting inflammatory bowel disease. The stock closed at €115.50, up 35% on the week. That kind of move in a pre-profitability biotech usually triggers a wave of short covering. Here, the signals are more mixed — and that tension is the story.
Short positioning remains firmly in place. The ORTEX short score ticked up to 78.4, close to its highest reading of the past two weeks, suggesting sustained pressure from the short side rather than a capitulation. Factor scores reinforce the picture: ABVX ranks in the 7th percentile on short score across the universe, and the 6th percentile on days-to-cover — both deep in heavily-shorted territory. Availability has tightened over the past week, dropping 16% to 53% — meaning for every two shares currently borrowed short, only about one remains available to lend. That's tight, though well above the 52-week floor of 9.2% hit earlier this year, when the borrow market was near fully exhausted. Cost to borrow remains modest at 2.7%, up 12% on the week and roughly 60% above month-ago levels, but nowhere near the kind of punishing rate that forces involuntary covering.
What makes the setup genuinely interesting is the divergence between price action and short conviction. Normally, a 39% day forces at least some re-evaluation from shorts. The stability of the short score above 78 — and availability tightening rather than loosening — suggests the bear case hasn't shifted much in their view. The availability history adds context: in late May, availability was above 1,000%, meaning shares to borrow were abundant. Since early June the pool has shrunk dramatically. Shorts built their positions into a much easier borrow environment; those who entered in June are now sitting on significant paper losses with a modestly tighter exit.
The Street picture is essentially absent as a near-term input. The only analyst data on record dates to October 2023 and carries a mean price target of €34.20 — stale by nearly three years and now deeply below the current price. There are no recent changes to report. ABIVAX is effectively unrated by active sell-side coverage for this note's purposes. Valuation multiples confirm the pre-commercial reality: the price-to-book has expanded to 153x over the past 30 days on the back of the share price rally, EPS yield is deeply negative, and EV/EBITDA is a loss-making -25x. The earnings momentum factor scores tell a more constructive story — 93rd percentile on 30-day EPS momentum and 77th on 90-day — suggesting forward estimates are being revised upward, even if profitability remains distant.
Recent earnings history offers some useful calibration. The last catalyst event in May produced a 9.5% one-day move and held most of that gain over five days. The March 2026 print went the other way, falling 5.3% on the day and extending losses to -7.5% over the week. The next scheduled event is September 21 — a long runway. Between now and then, the read on ABV-1454 trial progress will be the primary driver, with any interim clinical update capable of matching or reversing this week's move.
The key thing to watch into next week is whether availability continues to tighten: if it falls back toward the sub-20% levels seen in early June, that would signal fresh short demand into the rally — and the resulting squeeze dynamic could become a much louder story.
See the live data behind this article on ORTEX.
Open ABVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
